OssDsign - Waiting for sales momentum to improve
Transition of US sales team to drive a turnaround in sales generationNo change to mid-term targetsFair value range revised down to SEK 3.1-5.1 (3.2-5....
Transition of US sales team to drive a turnaround in sales generationNo change to mid-term targetsFair value range revised down to SEK 3.1-5.1 (3.2-5....
EU member states back non-renewal of Selektope approvalLimited impact on near-term financials; EU ~4% of salesStill positive on long-term prospects, b...
Q3'26 net sales SEK 178m vs ABGSCe SEK 178mEBITA SEK 24m vs ABGSCe SEK 24mThe share is trading at 7.3x/5.9x our '26e/'27e EV/EBITAQ3 in brief: In line...
42% beat (less negative) on adj EBIT but miss on sales-20% organic growth (ABGSCe -18%)No change in outlookQ3 resultsOssDsign reported a mixed set of ...
We raise our estimates following impressive Q3 profitabilityWe move to the very top of the FY EBITDA guidanceFVR up to DKK 8.5-11.5 (8.0-11.0)Impressi...
Q3 revenues in line with ABG, EBITDA 14% aboveFY'26 guidance reiteratedExpect consensus '26 EBITDA up 4-6%Q3 numbers vs. ABGSCeDONKEY delivered a stro...
Adj. EBITA up 21% y-o-y and 9% above ABGSCe despite weak salesWe cut ’26e/'27e/’28e adj. EBITA estimates by 2%/3%/5%Share trading at 14x/1...